Previous close | 0.7100 |
Open | 0.7100 |
Bid | 0.7500 |
Ask | 1.3000 |
Strike | 25.00 |
Expiry date | 2023-01-20 |
Day's range | 0.7100 - 0.7100 |
Contract range | N/A |
Volume | |
Open interest | 872 |
Company to host a webcast today at 4:30 p.m. Eastern Time NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal quarter end
Webcast and Conference Call To be Held Tuesday May 10, 2022, 4:30 pm ETNEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that it will issue financial r
Presentations cover the Psychometric Evaluation of the Rett Syndrome Behaviour Questionnaire (RSBQ) and the Burden of Illness (BOI) Study in Rett SyndromeNEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other